



Completes Phase 3 Recruitment for Lead Product Glypromate®

- Top level efficacy results to be released in 4Q 2008
- Data to date suggest that Glypromate® has an excellent safety profile
- Patient recruitment completed ahead of schedule and at less cost.

SYDNEY Australia 16 July 2008: Neuren Pharmaceuticals (ASX: NEU) today announced the completion of recruitment and dosing of patients into the Phase 3 trial of its lead product Glypromate®.

Glypromate® is designed to reduce brain impairment after major heart surgery. One third of patients suffer cognitive impairment three months after surgery and there is currently no approved treatment available to prevent this.

Neuren co-Chief Executive Officer Larry Glass said: "Completion of recruitment represents an exciting milestone for Neuren. It brings our lead drug another step closer to being commercially available and was achieved early and within our budget.

"The early trial data suggest that Glypromate® has an excellent safety profile. We are now collating the study data and look forward to the release of provisional efficacy results before the end of the year. The compound has the potential to significantly improve the quality of life for the large number of people who suffer cognitive impairment after cardiac bypass surgery.

"Achievement of recruitment ahead of schedule demonstrates how effective and efficient the team is at Neuren and our total focus on getting our promising treatments for central nervous system disorders and brain injury to market as soon as possible," Mr Glass said.

In June Neuren announced efficacy could be established with 320 patients, not 606 as first planned.

About Neuren

Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury and diseases and metabolic disorders. The Neuren portfolio comprises eight product families targeting markets with large unmet needs and limited competition. Neuren has three clinical-stage molecules — Glypromate®, Motiva™ and NNZ-2566 — focused on a range of acute and chronic neurological conditions. For more information visit www.neurenpharma.com.

For more information please contact: Larry Glass, Neuren Tel: +1 301 758 2987 or Andrew Geddes, Seed Media Tel: +61 408 677 734.